It never has been, and it is unlikely to be, because FDA approval requires hundreds of millions of dollars in clinical trial investment that no compounding pharmacy can justify for a generic combination
[DOI] [PMC free article] [PubMed] [Google Scholar] 319.Margier M., Le May C., Antoine T., Halimi C., Nowicki M., Lespine A., Reboul E
Animal studies have shown that the peptide exhibits anti-tumor activity and inhibits the expression of carcinogenic receptors [13]
Saxenda (for weight loss) will likely follow, as it uses the same active ingredient
When exposed to a hyperglycemic milieu, the GIPR was found to downregulate in a study of pancreatic islet cells (59) and the patients with T2DM might express a small amount of GIPR or defective GIPR (60, 61)
But I think it was a bold and much needed policy move, she said